Scientists at Griffith University's Institute for Glycomics and The Saban Research Institute of Children's Hospital Los Angeles have demonstrated that leukaemic cells can be eradicated by removing a carbohydrate modification displayed on the cell's surface.
The discovery is an important advance against leukaemia, a cancer of malignant white blood cells that multiply uncontrollably, said director of Griffith University's Institute for Glycomics, Professor Mark von Itzstein.
Acute lymphoblastic leukaemia (ALL) is the most common childhood cancer.
"We have found that the leukaemic cell has an altered cell surface carbohydrate decoration compared to normal cells and this also conveys resistance to drug treatment," von Itzstein said.
"By exploiting this 'Achilles heel' in these leukaemic cells, our collaborative research efforts are now focused on the development of a new type of drug therapy that targets this carbohydrate modification," von Itzstein said.
The study was published in the Journal of Experimental Medicine.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
